Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 16, 2015
Placebo-controlled study in neuromyelitis optica-Ethical and design considerationsBruce Ac Cree, Jeffrey L Bennett, Mark Sheehan, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.The Lancet. Neurology|May 17, 2024
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trialBruce A C Cree, Ho Jin Kim, Brian G Weinshenker, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentumBrian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.Ebiomedicine|November 12, 2022
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialJeffrey L Bennett, Orhan Aktas, William A Rees, et al.Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2021
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSDBruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 26, 2025
Gene-edited Pig Cardiac Xenotransplantation as a Bridge to Allotransplantation in Infants: Progress in a Pig-to-Baboon ModelJohn D Cleveland, Chace B Mitchell, William Swicord, et al.Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 27, 2021
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L Bennett, Ho Jin Kim, et al.Pageof 4